Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 39 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| EyePoint, Inc. | 7,288,479 | reported | 18 Apr 2024 | tx 19+2,500,822 |
| Apellis Pharmaceuticals, Inc. | 3,473,925 | reported | 13 Nov 2017 | tx 4+3,473,925−2,402,497 |
| Immuneering Corp | 3,295,273 | reported | 15 Mar 2024 | tx 5−909,091 |
| Corbus Pharmaceuticals Holdings, Inc. | 2,070,085 | reported | 20 Sept 2024 | tx 6+350,000 |
| MoonLake Immunotherapeutics | 1,994,173 | reported | 30 Sept 2025 | tx 5−6,499,978 |
| OnKure Therapeutics, Inc. | 1,813,439 | reported | 12 May 2025 | tx 1−24,300 |
| BRIGHT MINDS BIOSCIENCES INC. | 871,893 | reported | 16 Oct 2024 | tx 11+422,591 |
| Vigil Neuroscience, Inc. | 616,786 | reported | 11 Jan 2022 | tx 2+616,786−616,786 |
| Biomea Fusion, Inc. | 51.03 | reported | 12 Jun 2024 | tx 2+451,025 |
| Olema Pharmaceuticals, Inc. | 0 | reported | 23 Nov 2020 | tx 4+3,270,544−2,845,544 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 29 Sept 2025 | SALE | MoonLake Immunotherapeutics | 232,460 | 8.40 USD | |
| 29 Sept 2025 | SALE | MoonLake Immunotherapeutics | 70,748 | 9.38 USD | |
| 30 Sept 2025 | SALE | MoonLake Immunotherapeutics | 5,827 | 6.96 USD | |
| 29 Sept 2025 | SALE | MoonLake Immunotherapeutics | 3,390,943 | 7.58 USD | |
| 29 Sept 2025 | SALE | MoonLake Immunotherapeutics | 2,800,000 | 6.61 USD | |
| 12 May 2025 | SALE | OnKure Therapeutics, Inc. | 24,300 | 1.99 USD | |
| 15 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 2,600 | 8.80 USD | |
| 16 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 7,150 | 24.03 USD | |
| 15 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 238,097 | 4.53 USD | |
| 15 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 63,173 | 5.92 USD | |
| 15 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 33,343 | 6.42 USD | |
| 15 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 8,900 | 7.31 USD | |
| 16 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 3,107 | 25.22 USD | |
| 15 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 2,700 | 9.26 USD | |
| 15 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 19,169 | 11.72 USD | |
| 15 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 4,609 | 12.35 USD | |
| 16 Oct 2024 | PURCHASE | BRIGHT MINDS BIOSCIENCES INC. | 39,743 | 23.22 USD | |
| 20 Sept 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 25,943 | 18.36 USD | |
| 20 Sept 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 45,085 | 17.48 USD | |
| 20 Sept 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 25,769 | 22.23 USD | |
| 20 Sept 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 139,551 | 20.42 USD | |
| 20 Sept 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 66,088 | 19.61 USD | |
| 20 Sept 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 47,564 | 21.47 USD | |
| 12 Jun 2024 | GRANT_AWARD | Biomea Fusion, Inc. | 51,025 | 0.00 USD | deriv |
| 18 Apr 2024 | PURCHASE | EyePoint, Inc. | 186,521 | 18.90 USD |
2 purchases reported after at least 12 months of silence — most recent on 30 Mar 2023.